News
Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...
The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback